Sign In
Buy ALX
$281.63
-2.52 (-0.89%)
At Close: Jul 17, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
08:00am, Friday, 27'th Feb 2026
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anti
Alexander's (ALX) Upgraded to Buy: Here's What You Should Know
01:00pm, Thursday, 26'th Feb 2026
Alexander's (ALX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Finance Stocks Lagging Alexander's (ALX) This Year?
10:41am, Tuesday, 24'th Feb 2026
Here is how Alexander's (ALX) and Northern Trust Corporation (NTRS) have performed compared to their sector so far this year.
Beverly Hills Private Wealth LLC Increases Position in Alexander’s, Inc. $ALX
04:57am, Friday, 20'th Feb 2026
Beverly Hills Private Wealth LLC lifted its position in shares of Alexander's, Inc. (NYSE: ALX) by 13.0% during the third quarter, according to the company in its most recent filing with the SEC. The
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
08:33am, Thursday, 19'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapi
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
08:30am, Thursday, 19'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
Alexander’s (NYSE:ALX) versus Innovative Industrial Properties (NYSE:IIPR) Critical Comparison
01:39am, Thursday, 19'th Feb 2026
Innovative Industrial Properties (NYSE: IIPR - Get Free Report) and Alexander's (NYSE: ALX - Get Free Report) are both small-cap finance companies, but which is the superior stock? We will compare the
First Look: WBD waiver; Ackman's Meta bet; Ford-China JV
07:39am, Tuesday, 17'th Feb 2026
Stock News WBD reopens rival talks under Netflix waiver: Warner Bros. Discovery (WBD) received a seven-day waiver from Netflix (NFLX) to resume talks with Param
Alexander’s (NYSE:ALX) Stock Price Down 16.4% After Earnings Miss
01:56am, Tuesday, 10'th Feb 2026
Alexander's, Inc. (NYSE: ALX - Get Free Report)'s share price traded down 16.4% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $212.38 and last t
Alexander's (ALX) Misses Q4 FFO and Revenue Estimates
11:20am, Monday, 09'th Feb 2026
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.43 per share, missing the Zacks Consensus Estimate of $3.02 per share. This compares to FFO of $4.06 per share a year ago.
Alexander's Announces Fourth Quarter Financial Results
09:08am, Monday, 09'th Feb 2026
PARAMUS, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-K for the year ended December 31, 2025 today and reported:
Is Alexander's (ALX) Stock Outpacing Its Finance Peers This Year?
10:40am, Friday, 06'th Feb 2026
Here is how Alexander's (ALX) and Capital Southwest (CSWC) have performed compared to their sector so far this year.
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
01:38pm, Wednesday, 04'th Feb 2026
PARAMUS, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on Febru
ALX Oncology Announces Pricing of Underwritten Offering
08:30am, Friday, 30'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel thera
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer –
